FTC v. US Anesthesia Partners: Serial Acquisitions and Private Equity in Focus
Laurien Gilbert and Michael Richards of Cornell University will discuss the role of private equity firms in healthcare at this ABA event.
SEC Enforcement Actions Against Public Companies and Subsidiaries Jump in FY 2023
Total monetary value of settlements fell to lowest level in last eight fiscal years.
SEC Enforcement Activity: Public Companies and Subsidiaries—Fiscal Year 2023 Update
The SEC filed 91 enforcement actions against public companies and subsidiaries in fiscal year 2023, a 34% increase over FY 2022.
GCR Live: Women in Antitrust 2023
Avigail Kifer will join a panel titled, “Novel Theories of How Mergers Harm Competition” at this annual conference in Washington, DC.
Global Class Actions Symposium 2023
Vikram Kumar will chair a panel about calculating damages in large class actions at this London conference.
John Asker Appointed to New Australian Competition Taskforce Advisory Panel
Professor Asker joins an expert panel appointed to advise the Australian government on potential changes to the country's competition policy settings.
Bid Rigging and Umbrella Damages
This article analyzes the role of umbrella damages when conducting damage assessment in bid-rigging cases.
FMA’S 32nd Legal and Legislative Conference
Simona Mola will moderate a panel on “SEC Division Reports” during this in-person annual event in Washington, DC.
Public Workshops on the 2023 Draft Merger Guidelines
Justin McCrary of Columbia Law School discussed rebuttals and labor competition at this in-person event.
IBA 2023: International Bar Association Annual Conference
Joanna Tsai will speak on a panel titled “The Boundaries of Unilateral Conduct” at this annual conference in Paris.
San Francisco Bay Area Women’s Forum 2023: Sustaining a Positive Culture in a Changing Workplace
Professor Jennifer Chatman of the Haas School of Business presented at this networking event for professionals in the legal community.
Value Drug Company v. Takeda Pharmaceuticals U.S.A. Inc. et al.
Laurence Baker testified during a rare antitrust trial centering on the allegation that a brand manufacturer conspired with three generics to allocate the market for gout medication colchicine.
How can we help you?
If you are looking for a publication not on our website, contact us.